These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31367274)

  • 1. TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer.
    Ntavatzikos A; Spathis A; Patapis P; Machairas N; Vourli G; Peros G; Papadopoulos I; Panayiotides I; Koumarianou A
    World J Gastrointest Oncol; 2019 Jul; 11(7):551-566. PubMed ID: 31367274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating
    Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
    World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Khalij Y; Belaid I; Chouchane S; Amor D; Omezzine A; Ben Rejeb N; Ben Ahmed S; Bouslama A
    J Chemother; 2023 Sep; 35(5):425-434. PubMed ID: 36137946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
    Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymidylate synthase pharmacogenetics.
    Marsh S
    Invest New Drugs; 2005 Dec; 23(6):533-7. PubMed ID: 16267625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer.
    Jensen SA; Vainer B; Witton CJ; Jørgensen JT; Sørensen JB
    Acta Oncol; 2008; 47(6):1054-61. PubMed ID: 18607850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents.
    Yawata A; Kim SR; Miyajima A; Kubo T; Ishida S; Saito Y; Nakajima Y; Katori N; Matsumoto Y; Fukuoka M; Ohno Y; Ozawa S; Sawada J
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):465-72. PubMed ID: 15918040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression.
    Koumarianou A; Tzeveleki I; Mekras D; Eleftheraki AG; Bobos M; Wirtz R; Fountzilas E; Valavanis C; Xanthakis I; Kalogeras KT; Basdanis G; Pentheroudakis G; Kotoula V; Fountzilas G
    Anticancer Res; 2014 Sep; 34(9):4949-62. PubMed ID: 25202077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of genetic polymorphisms in the thymidylate synthase (TYMS) gene in methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia.
    Oosterom N; Berrevoets M; den Hoed MAH; Zolk O; Hoerning S; Pluijm SMF; Pieters R; de Jonge R; Tissing WJE; van den Heuvel-Eibrink MM; Heil SG
    Pharmacogenet Genomics; 2018 Oct; 28(10):223-229. PubMed ID: 30222710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.
    Murcia O; Juárez M; Rodríguez-Soler M; Hernández-Illán E; Giner-Calabuig M; Alustiza M; Egoavil C; Castillejo A; Alenda C; Barberá V; Mangas-Sanjuan C; Yuste A; Bujanda L; Clofent J; Andreu M; Castells A; Llor X; Zapater P; Jover R
    PLoS One; 2018; 13(9):e0203051. PubMed ID: 30188916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymidylate synthase gene polymorphism predicts disease free survival in stage II-III rectal adenocarcinoma patients receiving adjuvant 5-FU-based chemotherapy.
    Su X; Li S; Zhang H; Xiao H; Chen C; Wang G
    Chin Clin Oncol; 2019 Jun; 8(3):28. PubMed ID: 30823845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer.
    Renaud S; Romain B; Falcoz PE; Olland A; Santelmo N; Brigand C; Rohr S; Guenot D; Massard G
    Br J Cancer; 2015 Feb; 112(4):720-8. PubMed ID: 25688918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
    Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microsatellite Alterations With Allelic Loss at 9p24.2 Signify Less-Aggressive Colorectal Cancer Metastasis.
    Koi M; Garcia M; Choi C; Kim HR; Koike J; Hemmi H; Nagasaka T; Okugawa Y; Toiyama Y; Kitajima T; Imaoka H; Kusunoki M; Chen YH; Mukherjee B; Boland CR; Carethers JM
    Gastroenterology; 2016 Apr; 150(4):944-55. PubMed ID: 26752111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. G>C SNP of thymidylate synthase with respect to colorectal cancer.
    Gusella M; Padrini R
    Pharmacogenomics; 2007 Aug; 8(8):985-96. PubMed ID: 17716232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of microsatellite status on chemotherapy for colorectal cancer patients with
    Huang CJ; Huang SH; Chien CC; Lee HH; Yang SH; Chang CC; Lee CL
    Oncol Lett; 2016 Dec; 12(6):4427-4434. PubMed ID: 28101205
    [No Abstract]   [Full Text] [Related]  

  • 19. Alternative chemoradiotherapy in anal carcinoma patients with mutations in thymidylate synthase and dihydropyrimidine dehydrogenase genes.
    Saif MWM; Hamal R; Siddiqui N; Maloney A; Smith M
    Therap Adv Gastroenterol; 2021; 14():17562848211024464. PubMed ID: 34276810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer.
    Afzal S; Gusella M; Jensen SA; Vainer B; Vogel U; Andersen JT; Brødbæk K; Petersen M; Jimenez-Solem E; Adleff V; Budai B; Hitre E; Láng I; Orosz E; Bertolaso L; Barile C; Padrini R; Kralovánszky J; Pasini F; Poulsen HE
    Pharmacogenomics; 2011 Sep; 12(9):1257-67. PubMed ID: 21919605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.